Hyperoside Induces Apoptosis and Inhibits Growth in Pancreatic Cancer Via Bcl-2 Family and NF-κB Signaling Pathway Both in Vitro and in Vivo

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2015 Dec 18

PMID 26676634

Citations 19

Authors

Yilong Li

Yongwei Wang

Le Li

Rui Kong

Shangha Pan

Liang Ji

Huan Liu

Hua Chen

Bei Sun

Affiliations

Soon will be listed here.

Abstract

Although advanced surgical operation and chemotherapy have been under taken, pancreatic cancer remains one of the most aggressive and fatal human malignancies with a low 5-year survival rate of less than 5 %. Therefore, novel therapeutic strategies for prevention and remedy are urgently needed in pancreatic cancer. This present research aimed to investigate the anti-cancer effects of hyperoside in human pancreatic cancer cells. Our in vitro results showed that hyperoside suppressed the proliferation and promoted apoptosis of two different human pancreatic cancer cell lines, which correlated with up-regulation of the ratios of Bax/Bcl-2 and Bcl-xL and down-regulation of levels of nuclear factor-κB (NF-κB) and NF-κB's downstream gene products. What's more, using an orthotopic model of human pancreatic cancer, we found that hyperoside also inhibited the tumor growth significantly. Mechanically, these outcomes could also be associated with the up-regulation of the ratios of Bax/Bcl-2 and Bcl-xL and down-regulation of levels of NF-κB and NF-κB's downstream gene products. Collectively, our experiments indicate that hyperoside may be a promising candidate agent for the treatment of pancreatic cancer.

Citing Articles

New Evidence for Scop. Extracts Application in Gastrointestinal Ailments.

Stojkovic D, Dragicevic N, Ivanov M, Gajovic N, Jurisevic M, Jovanovic I Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861160 PMC: 11769289. DOI: 10.3390/ph18010098.

with the homology of medicine and food: a review of active ingredients, anticancer mechanisms, pharmacokinetics, quality control, toxicity and applications.

Ma P, Yuan L, Jia S, Zhou Z, Xu D, Huang S Front Oncol. 2024; 14:1446328.

PMID: 39314630 PMC: 11417411. DOI: 10.3389/fonc.2024.1446328.

Potential Implications of Hyperoside on Oxidative Stress-Induced Human Diseases: A Comprehensive Review.

Wang K, Zhang H, Yuan L, Li X, Cai Y J Inflamm Res. 2023; 16:4503-4526.

PMID: 37854313 PMC: 10581022. DOI: 10.2147/JIR.S418222.

Hyperoside as a UV Photoprotective or Photostimulating Compound-Evaluation of the Effect of UV Radiation with Selected UV-Absorbing Organic Compounds on Skin Cells.

Moukova A, Malina L, Kolarova H, Bajgar R Int J Mol Sci. 2023; 24(12).

PMID: 37373060 PMC: 10298051. DOI: 10.3390/ijms24129910.

Phytol and Heptacosane Are Possible Tools to Overcome Multidrug Resistance in an In Vitro Model of Acute Myeloid Leukemia.

Labbozzetta M, Poma P, Tutone M, McCubrey J, Sajeva M, Notarbartolo M Pharmaceuticals (Basel). 2022; 15(3).

PMID: 35337153 PMC: 8952646. DOI: 10.3390/ph15030356.

References

Liptay S, Weber C, Ludwig L, Wagner M, Adler G, Schmid R . Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer. 2003; 105(6):735-46. DOI: 10.1002/ijc.11081. View

Wang Y, Zhou Y, Zhou H, Jia G, Liu J, Han B . Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells. PLoS One. 2012; 7(8):e43826. PMC: 3429499. DOI: 10.1371/journal.pone.0043826. View

Arora S, Bhardwaj A, Srivastava S, Singh S, McClellan S, Wang B . Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. PLoS One. 2011; 6(6):e21573. PMC: 3123370. DOI: 10.1371/journal.pone.0021573. View

Sliva D . Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr Cancer Drug Targets. 2004; 4(4):327-36. DOI: 10.2174/1568009043332961. View

Llambi F, Green D . Apoptosis and oncogenesis: give and take in the BCL-2 family. Curr Opin Genet Dev. 2011; 21(1):12-20. PMC: 3040981. DOI: 10.1016/j.gde.2010.12.001. View

Greten F, Weber C, Greten T, Schneider G, Wagner M, Adler G . Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology. 2002; 123(6):2052-63. DOI: 10.1053/gast.2002.37075. View

Hiroshima Y, Maawy A, Hassanein M, Menen R, Momiyama M, Murakami T . The tumor-educated-macrophage increase of malignancy of human pancreatic cancer is prevented by zoledronic acid. PLoS One. 2014; 9(8):e103382. PMC: 4130525. DOI: 10.1371/journal.pone.0103382. View

Karin M . Nuclear factor-kappaB in cancer development and progression. Nature. 2006; 441(7092):431-6. DOI: 10.1038/nature04870. View

Chen H, Sun B, Wang S, Pan S, Gao Y, Bai X . Growth inhibitory effects of dihydroartemisinin on pancreatic cancer cells: involvement of cell cycle arrest and inactivation of nuclear factor-kappaB. J Cancer Res Clin Oncol. 2009; 136(6):897-903. DOI: 10.1007/s00432-009-0731-0. View

10.

Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. DOI: 10.3322/caac.20073. View

11.

Rylski M, REWERSKI W . The analgesic action of some flavonoids in the hot plate test. Acta Physiol Pol. 1979; 30(3):385-8. DOI: 10.103/00006450-01000-0000. View

12.

Wang Y, Wang S, Zhou Y, Pan S, Sun B . Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo. J Cancer Res Clin Oncol. 2012; 138(5):785-97. DOI: 10.1007/s00432-012-1152-z. View

13.

Wang Y, Zhou Y, Jia G, Han B, Liu J, Teng Y . Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway. Biochem Pharmacol. 2014; 88(3):322-33. DOI: 10.1016/j.bcp.2014.01.041. View

14.

Xiong H, Abbruzzese J, Lin E, Wang L, Zheng L, Xie K . NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer. 2003; 108(2):181-8. DOI: 10.1002/ijc.11562. View

15.

Bilimoria K, Bentrem D, Ko C, Ritchey J, Stewart A, Winchester D . Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007; 110(4):738-44. DOI: 10.1002/cncr.22852. View

16.

Maawy A, Hiroshima Y, Zhang Y, Heim R, Makings L, Garcia-Guzman M . Near infra-red photoimmunotherapy with anti-CEA-IR700 results in extensive tumor lysis and a significant decrease in tumor burden in orthotopic mouse models of pancreatic cancer. PLoS One. 2015; 10(3):e0121989. PMC: 4370703. DOI: 10.1371/journal.pone.0121989. View

17.

Kunnumakkara A, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal B . Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res. 2007; 67(8):3853-61. DOI: 10.1158/0008-5472.CAN-06-4257. View

18.

Fu X, Guadagni F, Hoffman R . A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A. 1992; 89(12):5645-9. PMC: 49349. DOI: 10.1073/pnas.89.12.5645. View

19.

Diehl J, Benzeno S . Cyclin D1 and pancreatic carcinoma: a proliferative agonist and chemotherapeutic antagonist. Clin Cancer Res. 2005; 11(16):5665-7. DOI: 10.1158/1078-0432.CCR-05-1016. View

20.

Oettle H . Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside. Cancer Treat Rev. 2014; 40(9):1039-47. DOI: 10.1016/j.ctrv.2014.07.003. View